IHC - Multiple Myeloma Panel from Bone Marrow / Tissue Biopsy Block

This test plays a crucial role in diagnosing and managing multiple myeloma by identifying abnormal plasma cells in bone marrow or tissue samples. These cells indicate the presence and progression of multiple myeloma, a type of blood cancer.

A positive result means that abnormal plasma cells were found in your bone marrow or tissue sample, suggesting the presence of multiple myeloma.

A negative result means that no abnormal plasma cells were detected, making the presence of multiple myeloma less likely. However, a negative result does not entirely rule out the disease.

The IHC - Multiple Myeloma Panel is typically recommended for individuals with symptoms of multiple myeloma, such as bone pain, frequent infections, fatigue, or other related signs. This test can also be useful for patients already diagnosed with multiple myeloma to understand the extent of the disease and determine the appropriate treatment strategy.

The test is performed on a bone marrow or tissue biopsy. The sample is treated with special antibodies that bind to specific proteins on plasma cells. The bound antibodies can then be visualized under a microscope.

No, fasting is not required for this test. You can continue your regular diet and medication schedule unless your healthcare provider instructs otherwise.

The IHC test itself poses minimal risk. However, the biopsy procedure used to obtain the tissue or bone marrow sample may carry some risks, including infection, bleeding, and discomfort at the biopsy site.

The quality of the biopsy sample and the specific methodology used for the test can potentially affect the test results. Factors such as recent infections or other medical conditions may also impact the results.

Abnormal test results should be discussed with your healthcare provider, who can provide further guidance based on your overall health, symptoms, and other diagnostic tests.

The frequency of this test will depend on your individual health circumstances and will be determined by your healthcare provider.

Coverage for this test will depend on your specific insurance plan. You should check with your insurance provider for coverage details.

There are other diagnostic procedures that can help diagnose multiple myeloma, such as blood tests, imaging tests, and other types of biopsies. However, the IHC - Multiple Myeloma Panel provides unique and valuable information.

No, a normal result does not guarantee the absence of multiple myeloma. It only indicates that no abnormal plasma cells were detected in the tested sample.

If your results are abnormal, you should consult a hematologist or an oncologist. These specialists can provide expert guidance on the next steps, including further diagnostic tests and potential treatment options.

Multiple myeloma treatment typically involves a combination of therapies including chemotherapy, radiation therapy, targeted therapy, immunotherapy, and in some cases, stem cell transplant.

The biopsy procedure usually doesn't require any specific preparations. However, it's important to inform your doctor about any medications or supplements you're currently taking, as some of these might increase the risk of bleeding. You may need to stop taking certain medications before the procedure.

The level of discomfort or pain varies depending on the type of biopsy and the area where the sample is taken from. Generally, a local anesthetic is used to numb the area and minimize discomfort during the procedure.

Recovery time after a biopsy varies depending on the type of biopsy and your general health. Most people can resume normal activities the day after the procedure. However, it may take a few days for the biopsy site to fully heal.

The reliability of the IHC - Multiple Myeloma Panel test is high when performed by a trained professional in a reliable lab. However, as with any test, there may be false positive or false negative results. The results should always be interpreted in conjunction with other diagnostic tests and clinical findings.

Yes, this test is safe for individuals who are pregnant or breastfeeding. However, if a biopsy is needed to get the sample, the risks associated with the biopsy procedure should be discussed with your doctor.

A bone marrow biopsy is generally considered a safe procedure with few long-term side effects. However, some people may experience ongoing pain, bleeding, or infection at the biopsy site. If you experience persistent discomfort or other unusual symptoms after a biopsy, contact your healthcare provider.

Other tests that might be ordered alongside this panel include complete blood count (CBC), protein electrophoresis,imaging tests (like X-ray, CT scan, or MRI) and genetic tests.